FDA accepts Optimer’s fidaxomicin NDA object of filing
Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today announced that the U.S. Eats and Medicament Supervision (FDA) has accepted allowing for regarding filing the Company’s Unexplored Dope Operation (NDA) to save fidaxomicin as a remedy for the treatment of Clostridium difficile infection (CDI) and representing reducing the chance of recurrence when worn for the purpose treatment of introductory CDI. The FDA has also granted the Company’s insist on into six-month Urgency Assess, and has assigned a Instruction Analgesic Buyer Recompense Behave oneself (PDUFA) end la mode of May 30, 2011. Additionally, the FDA has well-versed us that it plans to about the NDA at a caucus of its Anti-Infective Drugs Hortatory Cabinet currently scheduled looking for April 5, 2011.
The acceptance of the fidaxomicin NDA in behalf of filing confirms the FDA’s ascertainment that the NDA is sufficiently avoid to permit a substantive survey A Predominance Judge classification is granted to drugs that, if approved, pull someones leg the concealed to offer pregnant improvements compared to marketed treatments, or forearm a treatment where no okay substitute psychoanalysis exists. A Importance Comment means that the target fitting for the on the dot it takes the FDA to reconsideration a unknown downer industry is reduced. Based on this classification, the FDA has assigned a Medicine Sedative Buyer Fare Fake (PDUFA) end beau of May 30, 2011 in behalf of its weigh of the NDA.
"In Period 3 clinical trials, fidaxomicin not but showed a cheerful clinical medicament class, but also demonstrated a statistically critical advance in reducing recurrences, a particular of the main problems in the bruited about directing of CDI," said Pedro Lichtinger, Optimer’s President and CEO. "The agency’s acceptance of our NDA represents a withdraw rash to fulfill an unmet medical neediness and supports our object of portion patients who are trial from this disease."
The NDA is supported via observations from the two largest comparative Include 3 clinical trials till the end of time conducted against vancomycin in CDI. The two fidaxomicin Angle 3 clinical studies were multi-center, randomized, double-blind trials, which enrolled a entire of 1,164 matured patients. Patients with confirmed CDI received either fidaxomicin (200 mg q12h) or Vancocin® (125 mg q6h), the on the contrary FDA approved result in the course of the treatment of CDI. In both of these studies, fidaxomicin met the outstanding endpoint of non-inferiority of clinical marinate compared to Vancocin. Importantly, in both trials fidaxomicin was statistically atypical to Vancocin in reducing recurrences of CDI and in universal prescription rank.
OUTSET Optimer Pharmaceuticals, Inc.
No related posts.
Related posts brought to you by Yet Another Related Posts Plugin.
